Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.

Antimicrobial agents and chemotherapy - 1 Aug 2016

Almeida Deepak, Ioerger Thomas, Tyagi Sandeep, Li Si-Yang, Mdluli Khisimuzi, Andries Koen, Grosset Jacques, Sacchettini Jim, Nuermberger Eric

Abstract excerpt

The novel ATP synthase inhibitor bedaquiline recently received accelerated approval for treatment of multidrug-resistant tuberculosis and is currently being studied as a component of novel treatment-shortening regimens for drug-susceptible and multidrug-resistant tuberculosis. In a limited number of bedaquiline-treated patients reported to date, ≥4-fold upward shifts in bedaquiline MIC during treatment have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Diarylquinolines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred BALB C

Share to Microbial Sensitivity Tests

Share to Mutation

Share to Mycobacterium tuberculosis

Share to Tuberculosis, Multidrug-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 27185800
DOI: 10.1128/AAC.00753-16
PMCID: PMC4958187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.PMID 27185800Read ↗

Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.Semantic proximity Read ↗

Acquired resistance of Mycobacterium tuberculosis to bedaquiline.Semantic proximity Read ↗

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678Semantic proximity Read ↗

Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysisSemantic proximity Read ↗

Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Deciphering Bedaquiline and Clofazimine Resistance in Tuberculosis: An Evolutionary Medicine ApproachSemantic proximity Read ↗

Mutations in Rv0678, Rv2535c, and Rv1979c Confer Resistance to Bedaquiline in Clinical Isolates of Mycobacterium Tuberculosis.Semantic proximity Read ↗

Bedaquiline Resistance: Its Emergence, Mechanism, and PreventionSemantic proximity Read ↗

Detection of a historic reservoir of bedaquiline / clofazimine resistance associated variants in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

Verapamil and its metabolite norverapamil inhibit the <i>Mycobacterium tuberculosis</i> MmpS5L5 efflux pump to potentiate the activity bedaquiline and other antitubercular drugsSemantic proximity Read ↗

Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung DiseaseSemantic proximity Read ↗

Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.